LYC Healthcare: Progress Amid Challenges
LYC Healthcare’s latest Q2 FY2025 results reflect steady progress, with revenue rising 29% year-on-year to RM41.74 million from RM32.01 million. This growth was driven by strong performance in its nutraceutical, clinical, and confinement businesses, alongside contributions from new subsidiaries. The group also recorded a profit before tax of RM1.55 million, a significant improvement from a loss of RM2.04 million in the same quarter last year.
Regionally, Malaysia's revenue surged by 41% to RM27.81 million (Q2 FY2024: RM19.71 million), supported by growth in confinement and nutraceutical segments, while losses before tax narrowed from RM3.51 million to RM0.77 million. Singapore's revenue grew 33% to RM16.93 million (Q2 FY2024: RM12.74 million), though profit before tax eased slightly to RM1.39 million from RM1.47 million due to higher operating costs.
While net losses attributable to owners widened to RM2.77 million, impacted by foreign exchange losses and rising costs, the group remains focused on strategic realignments, including divestments and new partnerships. These moves position LYC to leverage healthcare megatrends, despite ongoing challenges.
Price Movement Overview
• The share price of LYC Healthcare Berhad has shown a notable downtrend from April to September, declining from a high of approximately RM0.185 to a low of RM0.075.
• In recent weeks, the price appears to be stabilising around RM0.08–RM0.10, with minor upward movement indicating potential consolidation.
Key Levels
• Support Level: The price found strong support at RM0.06 in September, with buyers stepping in to prevent further decline.
• Resistance Level: Immediate resistance is at RM0.10, which the price is testing currently.
• Breakout Potential: A sustained breakout above RM0.10 could see the share price targeting RM0.12 or higher, given the current upward momentum.
How well do narratives help inform your perspective?
Disclaimer
The user Ontological holds no position in KLSE:LYC. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.